Vermillion, Inc., a molecular diagnostics company based in Austin, has a new President and CEO – Thomas McLain. Interim Chief Executive Officer, Bruce Heubner, will remain on as company director and to facilitate a smooth transition and shift in leadership.
Mr. McLain is a 20-year veteran of executive management and corporate governance, having worked with both publicly and privately-held companies in the past. His particular strength over the span of his career has been to turn medical diagnostic and biotechnology industry companies into true leaders within their sectors.
According to a press release on PR Newswire:
“We expect to benefit from Tom’s seasoned skills, abilities and insights as we pursue strategies that expand our product pipeline and advance the development and commercial adoption of our diagnostic tests,” said James S. Burns , Vermillion’s chairman of the board. “We look forward to Tom’s leadership in building a preeminent company in diagnostic tests that address unmet clinical needs in women’s health, particularly in ovarian and other oncological cancers. We’re also confident he will help broaden the use of our lead diagnostic test, OVA1®, which is unmatched in detecting ovarian cancer.”
Vermillion, Inc.’s company efforts are focused on furthering diagnostic programs in oncology, vascular health and women’s health. One of their more popular diagnostic developments, the OVA1®, uses a distinct multi-biomarker concept in order to assess the malignancy of tumors prior to performing surgery. OVA1® is unmatched, with clinical trial results boasting a 99% sensitivity in screening for epithelial ovarian cancers (EOC).